The potential of dopamine agonists in drug addiction

Expert Opinion on Investigational Drugs

Volumn 11, Issue 4, 2002, Pages 491-499

  Kosten, Thomas R ^a   George, Tony P ^a   Kosten, Therese A ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Alcohol dependence; Cocaine dependence; Dopamine agonists; Humans; Nicotine dependence; Pharmacotherapy

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ADROGOLIDE; ALCOHOL; ALDEHYDE DEHYDROGENASE INHIBITOR; AMANTADINE; AMFEBUTAMONE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; COCAINE; DISULFIRAM; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG; MAZINDOL; METHADONE; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NICOTINE; NORTRIPTYLINE; PERGOLIDE; PLACEBO; RECEPTOR SUBTYPE; SELEGILINE; UNINDEXED DRUG;

ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALCOHOLISM; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SCREENING; FEMALE; GENOTYPE; HUMAN; MALE; NONHUMAN; RAT; REVIEW; SIDE EFFECT; SMOKING;

ALCOHOL-RELATED DISORDERS; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 0036237715     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.4.491     Document Type: Review

References (88)

1. Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal
2. Dopaminergic responsivity during cocaine abstinence: A pilot study
3. Serum prolactin levels during extended cocaine abstinence
4. The pharmacology of cocaine related to its abuse
5. Neural mechanisms of drug reinforcement
6. Dopaminergic systems in the brain and pituitary
7. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
8. Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system
9. Differential behavioral responses to cocaine are associated with dynamics of mesolimbic proteins in Lewis and Fischer 344 rats
10. Significant differences in the activity of midbrain dopamine neurons between male Fischer 344 (F344) and Lewis rats: An in vivo electrophysiological study
11. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats
12. Extracellular dopamine and its metabolites in the nucleus accumbens of Fischer and Lewis rats: Basal levels and cocaine-induced changes
13. Morphine-induced locomotor activity and dopamine overflow in the nucleus accumbens in Lewis and Fischer 344 inbred rat strains: A comparative study
14. Lewis and Fischer rats: A comparison of dopamine transporter and receptors levels
15. Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats
16. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption
17. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: Genetic and motivational determinants
18. Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: Reversal by increasing synaptic dopamine
19. Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse
20. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele
21. Bromocriptine in the treatment of the alcohol-withdrawal syndrome
22. Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms
23. Bromocriptine in the prevention of alcohol abuse
24. Bromocriptine in the treatment of alcohol dependence
25. Long-acting injectable bromocriptine does not reduce relapse in alcoholics
26. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders
27. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence
28. Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics
29. Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats
30. Cocaine and other stimulants: Actions, abuse and treatment
31. Effects of bromocriptine pretreatment on subjective and physiological responses to IV cocaine
32. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence
33. A randomized trial of bromocriptine for cocaine users presenting to the emergency department
34. Effects of pergolide on intravenous cocaine self-administration in men and women
35. Pergolide mesylate: Adverse events occurring in the treatment of cocaine dependence
36. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans
37. Selective inhibition of cocaine seeking behavior by a partial dopamine D3 receptor agonist
38. Replacement medication for cocaine dependence: Methylphenidate
39. Effects of cocaine alone and in combination with mazindol in human cocaine abusers
40. Mazindol treatment for cocaine dependence
41. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients
42. Acute and chronic amantadine pre-treatment attenuates some of cocaine's effect in human subjects
43. Amantadine may facilitate detoxification of cocaine addicts
44. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline
45. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria
46. Disulfiram effects on acute cocaine administration
47. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
48. Bupropion is a nicotinic antagonist
49. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking
50. Clinical pharmacokinetics and pharmacodynamics of selegiline
51. Effects of monoamine inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
52. Effects of repeated nicotine pre-treatment on mesoprefontal dopaminergic and behavioral responses to acute footshock stress
53. Effects of nicotine withdrawal on central dopaminergic systems
54. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome
55. Changes in urinary catecholamine excretion after smoking cessation
56. Urinary adrenaline concentrations during 10 days of smoking abstinence
57. Psychological and physiological changes during tobacco abstinence in habitual smokers
58. The clinical potential of Deprenyl in neurologic and psychiatric disorders
59. Are metabolites of L-deprenyl (selegiline) useful or harmful?: Indications from preclinical research
60. Evaluation of physical dependence liability of L-deprenyl (selegiline) in animals
61. A preliminary trial of selegiline hydrochloride versus placebo for smoking cessation
62. Recent advances in the pharmacotherapy of smoking
63. Selegiline and transdermal nicotine for smoking cessation
64. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats
65. Inhibition of monoamine oxidase B in the brains of smokers
66. Brain monoamine oxidase A inhibition in cigarette smokers
67. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers
68. Dopamine receptor agonists, partial agonists and psychostimulant addiction
69. A-ergic ligands
70. Affinity and intrinsic activity in the theory of competitive inhibition
71. The pharmacology of vascular smooth muscle
72. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys
73. The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats
74. Pharmacological blocking agents for treating substance abuse
75. Decreased striatal dopaminergic responsivity in detoxified cocaine abusers
76. Behavior genetic investigation of the relationship between spontaneous locomotor activity and the acquisition of morphine self-administration behavior
77. Acquisition and maintenance of intravenous cocaine self-administration in Lewis and Fischer inbred rat strains
78. Selective effects of the D1 dopamine agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkey
79. Differential modulation of behavioral effects of cocaine in squirrel monkeys: Involvement of dopamine receptor subtypes
80. Drug discrimination in methamphetamine-trained monkeys: Agonist and antagonist effects of dopaminergic drugs
81. Dopamine D3 receptor agents as potential new medications for drug addiction
82. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism
83. D3 dopamine receptor, behavioral sensitization, and psychosis
84. Modulation of cocaine self-administration in the rat through D3 dopamine receptors
85. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat
86. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities
87. Homozygosity at the dopamine D3 receptor gene is associated with opioid dependence
88. The genetics of addiction: Alcohol-dependence and D3 dopamine receptor gene